ArticleCureus2025
Impact of Continuous Positive Airway Pressure Therapy on Diabetes Control in Patients With Obstructive Sleep Apnea at a Tertiary Hospital in Saudi Arabia: A Retrospective Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObstructive sleep apnea (OSA) is highly prevalent among patients with type 2 diabetes mellitus (T2DM) and is recognized as an independent contributor to insulin resistance and poor glycemic control through mechanisms such as intermittent hypoxia, sleep fragmentation, and sympathetic overactivity. Continuous positive airway pressure (CPAP) therapy is the standard treatment for OSA and has been shown to improve respiratory parameters; however, evidence regarding its metabolic benefits remains inconsistent, particularly in real-world clinical practice where adherence and disease severity vary.
objectiveTo evaluate changes in glycemic and metabolic parameters following CPAP therapy in patients with coexisting OSA and T2DM and to examine the influence of CPAP adherence, OSA severity, and baseline glycemic control on treatment outcomes.
methodsA retrospective cohort study was conducted at King Fahad Hospital of the University, including adults diagnosed with both OSA and T2DM between 2018 and 2025. Demographic data, polysomnography results, and metabolic parameters were obtained from electronic medical records. Glycemic and metabolic markers were compared before and after six months of CPAP therapy. Subgroup analyses were performed according to CPAP adherence status, apnea severity, and baseline glycated hemoglobin (HbA1c) levels. Statistical analyses were performed using SPSS version 26 (IBM Corp., Armonk, NY, USA).
resultsA total of 112 patients were included in the study with a mean age of 54.2 years, and 57.1% were male. After six months of CPAP therapy, median HbA1c levels significantly decreased from 7.15% to 6.9%. Greater reductions in HbA1c were observed among patients adherent to CPAP therapy (7.55% to 6.25%), those with severe OSA (7.1% to 6.8%), and patients with baseline HbA1c levels greater than 9% (10% to 8.6%). No statistically significant changes were observed in lipid profile parameters or blood pressure measurements.
conclusionCPAP therapy was associated with improved glycemic control in patients with OSA and T2DM, particularly among those with higher adherence to CPAP, severe OSA, and poor baseline glycemic control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.